ArticleThe Pediatric infectious disease journal2026
Clinical Characteristics of Enterovirus D68 Respiratory Disease in Colorado Children Over a Decade: 2014-2025.
Article in The Pediatric infectious disease journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundEnterovirus D68 (EV-D68) causes cyclical outbreaks worldwide. Though EV-D68 can rarely cause acute flaccid myelitis, it commonly causes respiratory disease. In particular, EV-D68 causes outbreaks of severe asthma-like respiratory disease, but few systems have the capability to detect EV-D68 cases.
methodsActive, prospective EV-D68 surveillance at Children's Hospital Colorado has been performed since 2014, where a random subset of residual clinical respiratory specimens, primarily from inpatient settings, and positive for rhinovirus/enterovirus are tested for EV-D68 via reverse transcription-polymerase chain reaction. Data via chart review from this surveillance were analyzed from 2014 to 2025 to characterize the clinical characteristics of EV-D68 respiratory disease in children (<18 years).
resultsFrom 2014 to 2025, EV-D68 was detected in 308 patients, of which 271/308 (88%%) were children with respiratory disease. Median age of children with respiratory disease was 6 [interquartile range (IQR): 3.1-10.4] years; 162/271 (59.8%) were males. A majority of children admitted required intensive care unit admission (206/258, 79.8%). Though only 174/271 (64.2%) children had an atopic history, a significant majority required bronchodilator therapy (249/271, 91.9%) and systemic steroids (229/271, 84.5%). Median intensive care unit and hospital length of stay were 2 (IQR: 1-3) and 3 (IQR: 2-5) days, respectively.
conclusionsChildren with EV-D68 respiratory disease commonly presented with severe asthma-like respiratory disease, even in those without atopy. Despite the severity of disease, children quickly improved over short hospitalizations when managed with bronchodilators, steroids, and respiratory support. With improved diagnostics to detect and recognize the true burden of EV-D68, additional studies evaluating short- and long-term management of EV-D68 respiratory disease are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.